Axiom Investors LLC DE Acquires New Shares in Integer Holdings Corporation $ITGR

Key Points

• Axiom Investors LLC DE has acquired 37,772 shares of Integer Holdings Corporation, valued at approximately $4.46 million, which represents about 0.11% of the company.
• Integer Holdings has seen significant institutional interest, with 99.29% of its stock owned by institutional investors and hedge funds, and multiple firms increasing their stakes in the first quarter.
• Analysts have mixed ratings on Integer, with a consensus rating of "Buy" and a target price averaging $140.25, despite recent downgrades from firms like Wells Fargo and Truist Financial.

Axiom Investors LLC DE purchased a new position in Integer Holdings Corporation (NYSE:ITGR - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 37,772 shares of the medical equipment provider's stock, valued at approximately $4,457,000. Axiom Investors LLC DE owned about 0.11% of Integer at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ITGR. Vaughan Nelson Investment Management L.P. purchased a new position in shares of Integer in the 1st quarter worth about $33,337,000. Nuveen LLC purchased a new position in shares of Integer in the 1st quarter worth about $17,634,000. GAMMA Investing LLC raised its holdings in shares of Integer by 8,697.6% in the 1st quarter. GAMMA Investing LLC now owns 78,123 shares of the medical equipment provider's stock worth $92,190,000 after purchasing an additional 77,235 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Integer in the 4th quarter worth about $7,889,000. Finally, Northern Trust Corp raised its holdings in shares of Integer by 14.2% in the 4th quarter. Northern Trust Corp now owns 422,380 shares of the medical equipment provider's stock worth $55,974,000 after purchasing an additional 52,556 shares during the period. 99.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Integer

In other news, Director Martin C. Maxwell sold 8,720 shares of Integer stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $120.56, for a total value of $1,051,283.20. Following the completion of the transaction, the director owned 22,170 shares in the company, valued at approximately $2,672,815.20. This trade represents a 28.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Donald J. Spence sold 14,739 shares of Integer stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total value of $1,774,280.82. Following the completion of the transaction, the director owned 18,781 shares of the company's stock, valued at approximately $2,260,856.78. The trade was a 43.97% decrease in their position. The disclosure for this sale can be found here. 2.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ITGR. Raymond James Financial cut their price objective on Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a report on Friday, July 25th. Wall Street Zen upgraded Integer from a "sell" rating to a "hold" rating in a report on Monday, May 19th. Citigroup upgraded Integer from a "hold" rating to a "strong-buy" rating and raised their target price for the company from $133.00 to $140.00 in a report on Thursday, May 22nd. Truist Financial dropped their target price on Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a report on Friday, July 25th. Finally, Wells Fargo & Company dropped their target price on Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a report on Friday, July 25th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $140.25.

Integer Stock Up 0.0%

NYSE ITGR traded up $0.02 during mid-day trading on Friday, reaching $107.40. 31,973 shares of the company's stock traded hands, compared to its average volume of 470,699. Integer Holdings Corporation has a 1-year low of $104.93 and a 1-year high of $146.36. The company has a fifty day simple moving average of $112.91 and a 200-day simple moving average of $118.31. The company has a current ratio of 3.41, a quick ratio of 2.18 and a debt-to-equity ratio of 0.72. The company has a market cap of $3.76 billion, a price-to-earnings ratio of 47.29, a P/E/G ratio of 0.85 and a beta of 1.02.

Integer (NYSE:ITGR - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.02). Integer had a net margin of 4.61% and a return on equity of 12.27%. The business had revenue of $476.00 million for the quarter, compared to analyst estimates of $464.37 million. During the same quarter last year, the business earned $1.30 EPS. Integer's revenue for the quarter was up 11.4% compared to the same quarter last year. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. As a group, equities research analysts expect that Integer Holdings Corporation will post 6.01 EPS for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.